Silverarc Capital Management’s C4 Therapeutics CCCC Stock Holding History

Silverarc Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.2M	Buy	3,032,060 +1,120,275	+59%	+$3.83M	1.47%	23
2026 Q1	$5.03M	Sell	1,911,785 -82,439	-4%	-$194K	0.51%	43
2025 Q4	$3.81M	Buy	1,994,224 +96,841	+5%	+$229K	0.53%	45
2025 Q3	$4.21M	Buy	+1,897,383	New	+$4.55M	0.57%	46
2025 Q2	–	Sell	-882,300	Closed	-$1.41M	–	71
2025 Q1	$1.41M	Sell	882,300 -338,831	-28%	-$1.01M	0.29%	54
2024 Q4	$4.4M	Buy	1,221,131 +73,240	+6%	+$364K	0.96%	34
2024 Q3	$6.54M	Sell	1,147,891 -294,950	-20%	-$1.78M	1.47%	22
2024 Q2	$6.67M	Buy	1,442,841 +6,910	+0.5%	+$41.2K	1.57%	20
2024 Q1	$11.7M	Buy	+1,435,931	New	+$11.1M	3.26%	9

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Silverarc Capital Management's CCCC Position: Q2 2026 in Review

Silverarc Capital Management increased its C4 Therapeutics (CCCC) stake by 59% in Q2 2026, buying an estimated $3.83M and bringing the position to 3,032,060 shares worth $14.2M. The position accounts for 1.47% of the portfolio, ranked #23.

Silverarc Capital Management first reported a position in CCCC in Q1 2024 and has held it in 9 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Silverarc Capital Management held 3,032,060 shares of C4 Therapeutics worth $14.2M as of Q2 2026.
Silverarc Capital Management bought 1,120,275 C4 Therapeutics shares in Q2 2026, an estimated $3.83M.
C4 Therapeutics made up 1.47% of Silverarc Capital Management's portfolio in Q2 2026, its #23 holding.
Silverarc Capital Management first reported a position in C4 Therapeutics in Q1 2024 and has held it in 9 quarters since.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.